Skip to content

Evaluation of the efficacy of air quality warning in stable intervention in patients with chronic obstructive pulmonary disease (COPD) : a prospective randomized controlled study

Evaluation of the efficacy of air quality warning in stable intervention in patients with chronic obstructive pulmonary disease (COPD) : a prospective randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116479
Enrollment
Unknown
Registered
2026-01-11
Start date
2024-12-28
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Intervention group 2 (air quality warning and forecasting wechat mini program intervention):Air quality warning and forecasting wechat mini program intervention
Intervention Group 1 (Publicity and Education Intervention):Publicity and Education Intervention
Control group:Receive routine COPD management, including medical services, medication, and basic health education.

Sponsors

Shanghai Fifth Peoople's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Aged 40-80 years old, with Shanghai registration, permanent residents of Jiangchuan Road, Zhuanqiao Town and Maqiao Town in Minhang District. 2.It meets the diagnostic criteria for stable COPD in the Diagnosis and Treatment Guidelines for Chronic Obstructive Pulmonary Disease (Revised 2021). 3.Patients are willing to participate in the study and sign informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients who are currently in an acute exacerbation or are at high risk of acute exacerbation during a stable period; 2.Patients who are unable to cooperate with lung function tests or have contraindications in lung function tests; 3.Patients with severe mental illness or cognitive impairment; 4.Patients with severe cardiovascular and cerebrovascular diseases; 5.Patients who are pregnant, participate in other clinical trial interventions, or have special circumstances such as limited activities; 6.Patients who are already receiving specific treatment or have other major health problems; 7.Patients had received other treatments or interventions in the past that could have affected the study results.

Design outcomes

Primary

MeasureTime frame
The number of acute exacerbations during the intervention period;

Secondary

MeasureTime frame
C-reactive Protein;Forced Expiratory Volume in One Second / Forced Vital Capacity;Forced Expiratory Volume in One Second;Peak Expiratory Flow;modified Medical Research Council Dyspnea Scale Score;Toll-like Receptor 4;Tumor Necrosis Factor-a;Interleukin-33;St. George's Respiratory Questionnaire Score;COPD Assessment Test Score;Annual average number of hospitalizations / costs;

Countries

China

Contacts

Public ContactXiaohua Zhang

Shanghai Fifth Peoople's Hospital

747523586@qq.com+86 21 2428 9097

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026